HDAC6 / Protein deacetylase HDAC6 · IHC design guide

Design Immunohistochemistry for HDAC6

Plan HDAC6 paraffin-section IHC around cytoplasmic staining in most cell types, including abundant staining in renal tubules and seminiferous ducts (HPA tissue IHC). This guide covers catalog antibody conditions (datasheet PB9628) and the low consistency between tissue staining and RNA expression (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for HDAC6 (IHC for HDAC6): expected localisation Cytoplasmic staining in most cell types (HPA tissue IHC), antibody PB9628, validated IHC image, and IHC protocol steps — Printable **HDAC6** IHC protocol sheet — expected localisation Cytoplasmic staining in most cell types (HPA tissue IHC), antibody PB9628, controls and protocol steps. Open the full HDAC6 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

HDAC6 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining in most cell types (HPA tissue IHC)
	Staining pattern	Cytoplasmic staining, most abundant in renal tubules and seminiferous ducts (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet PB9628)
	Positive control ⓘ	Breast+4 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific)
	Caveat	Staining and RNA expression show low consistency (HPA tissue IHC)
	Regulation	Valine loss promotes nuclear entry (UniProt)
	Isoform / epitope	2 isoforms; shared epitope coverage is unknown (UniProt)

Section 1

Recommended HDAC6 IHC & IF Protocols

The catalog antibody’s IHC-P protocol (datasheet: PB9628) is accompanied by three published HDAC6 staining methods for paraffin sections (PMC12127455; PMC13256419; PMC7751721).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet PB9628)
Fixation	Image fixative and duration unreported (datasheet PB9628); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet PB9628); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB9628)
Primary antibody	Rabbit anti-HDAC6, 2-5 μg/ml (datasheet PB9628)
Primary incubation	Overnight at 4 °C (datasheet PB9628)
Detection	HRP-conjugated secondary, DAB chromogen (datasheet PB9628)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	HDAC6-positive staining in glandular cells of breast (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most cell types, most abundant in renal tubules and cells in seminiferous ducts. No signal in the no-primary control.

💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 (datasheet: PB9628); the published methods provide conditions to compare during optimization (PMC12127455; PMC13256419; PMC7751721).

Section 2

What Is the Expected HDAC6 Staining Pattern?

HDAC6 is mainly cytoplasmic and associated with microtubules, with context-dependent nuclear localization (UniProt Q9UBN7). In tissue IHC, expect cytoplasmic staining across many cell types, especially renal tubules and cells in seminiferous ducts (HPA tissue IHC). Breast glandular cells, skin keratinocytes and pachytene spermatocytes are reported as high-staining examples (HPA tissue IHC). HPA rates its tissue IHC evidence Supported but notes low consistency between antibody staining and RNA expression (HPA tissue IHC).

What am I looking at on my slide?
Cytoplasmic chromogen in breast glandular cells, skin keratinocytes or pachytene spermatocytes, with readable cell boundaries.	This fits the expected compartment (UniProt Q9UBN7) and reported high-staining cells (HPA tissue IHC). Judge intensity against neighboring cells and the same run’s controls; a high HPA category does not prescribe one absolute chromogen intensity.
Strong membrane-rim or extracellular staining dominates, with little discernible cytoplasm.	Treat that distribution as suspect: HDAC6 has no transmembrane segment and is mainly cytoplasmic (UniProt Q9UBN7). Recheck morphology and control slides before assigning the signal to HDAC6.
Prominent staining appears in adipocytes or skeletal myocytes while an expected positive cell population is weak.	HPA reports HDAC6 as not detected in those cell types (HPA tissue IHC). Cross-reactivity or endogenous detection activity is possible; the mismatch warrants controls, not an immediate biological conclusion.
Diffuse chromogen covers several tissue structures without clear cell-level localization.	That pattern cannot establish the mainly cytoplasmic distribution reported for HDAC6 (UniProt Q9UBN7). In general IHC practice, nonspecific antibody staining or detection background can obscure a genuine signal.
No staining appears in a selected high-staining cell population, including on the run’s positive-control section.	A failed run or insufficient detection is possible; first establish that the control tissue and its target cells are present. HPA reports high staining in breast glandular cells, skin keratinocytes and pachytene spermatocytes, with a Supported reliability rating and an RNA–staining consistency caveat (HPA tissue IHC).

💡Expected HDAC6 appearanceCall a result positive when identifiable expected cells show predominantly cytoplasmic chromogen, with comparatively strong staining in an HPA high-staining population; dominant membrane-rim, extracellular or structure-wide diffuse color is suspect (UniProt Q9UBN7; HPA tissue IHC).

How each factor affects the staining
Compartment and topology (UniProt Q9UBN7)	HDAC6 is mainly cytoplasmic, associates with microtubules and has no transmembrane segment (UniProt Q9UBN7). Assess intracellular staining against cell morphology; membrane or extracellular color does not match its annotated location.
Nuclear signal and IF/ICC interpretation (UniProt Q9UBN7; HPA subcellular)	IF/ICC: where can signal occur? HPA supports cytosol, centrosome and basal body localization but marks additional nucleoplasm localization uncertain (HPA subcellular). UniProt reports cytoplasm-to-nucleus shuttling (UniProt Q9UBN7). Nuclear signal merits contextual review rather than automatic rejection.
Cell-type reference and evidence limit (HPA tissue IHC)	HPA reports high staining in breast glandular cells, skin keratinocytes and pachytene spermatocytes, and no detection in adipocytes or skeletal myocytes (HPA tissue IHC). These are reference patterns, not universal positive and negative guarantees: HPA notes low RNA–staining consistency.
Antibody validation (HPA antibodies)	HPA003714, HPA026321 and CAB004236 each have Supported IHC status (HPA antibodies). Their ICC status differs or is unreported, so IHC validation alone does not settle an IF/ICC localization discrepancy.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Expected positive cells and the run’s positive control are blank.	The assay may have failed, or the intended target cells may be absent from the examined section; HPA’s high-staining examples are cell-specific (HPA tissue IHC).	Confirm the cell population on the counterstained section. Then review the run’s primary-antibody, detection and chromogen steps using general IHC controls before interpreting the sample as negative.
The section shows mostly nuclear staining.	HDAC6 can shuttle to the nucleus (UniProt Q9UBN7), although its main location is cytoplasmic; HPA calls nucleoplasm an uncertain additional IF/ICC location (HPA subcellular).	Compare the nuclear signal with cytoplasmic staining, morphology and controls. Record a predominantly nuclear result as a departure from the usual pattern; do not dismiss all nuclear staining solely by compartment.
Chromogen outlines membranes or fills extracellular spaces.	That distribution conflicts with the mainly cytoplasmic location and lack of a transmembrane segment (UniProt Q9UBN7); background or misread tissue boundaries may contribute.	Re-examine cell boundaries under the counterstain and compare with a no-primary control. Reassess the run if the same edge or extracellular color appears without primary antibody.
Adipocytes, skeletal myocytes or other unexpected cells stain more strongly than the selected positive cells.	HPA reports no detection in adipocytes and skeletal myocytes (HPA tissue IHC). Cross-reactivity or endogenous detection activity is possible, though HPA’s tissue evidence has an RNA–staining consistency caveat.	Verify cell identity, inspect a no-primary control for detection background and compare the expected positive population on the same run. Avoid calling an unexpected cell type positive from color alone.
Color is diffuse across the section and cellular localization cannot be scored.	General IHC practice: nonspecific primary-antibody binding or endogenous detection activity can produce widespread background that masks a compartment-specific signal.	Compare no-primary and detection controls; review blocking, antibody concentration, washes and endogenous-activity control as appropriate to the detection system. Score HDAC6 only where cell-level cytoplasmic localization remains discernible (UniProt Q9UBN7).
Two antibodies give different cell distributions or intensities.	HPA assigns Supported IHC status to HPA003714, HPA026321 and CAB004236, yet its tissue summary notes low consistency between antibody staining and RNA expression (HPA antibodies; HPA tissue IHC).	Compare like-for-like sections, identify the same cell types and review each antibody’s controls. Report the disagreement and limit conclusions to reproducible compartment and cell-level patterns.

Source: UniProt Q9UBN7 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing HDAC6 staining

IHC analysis of HDAC6 using anti-HDAC6 antibody (PB9628). HDAC6 was detected in a paraffin-embedded section of human breast cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-HDAC6 Antibody (PB9628) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

PB9628 · IHCIHC analysis of HDAC6 using anti-HDAC6 antibody (PB9628). HDAC6 was detected in a paraffin-embedded section of human breast cancer tissue. H

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000094631-HDAC6/tissue/cerebral+cortex#imid_1474572

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000094631-HDAC6/tissue/colon#imid_1474498

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000094631-HDAC6/tissue/liver#imid_1474499

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000094631-HDAC6/tissue/kidney#imid_1474500

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA026321; green = HDAC6, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for HDAC6 IHC & IF

🧪Run breast first; glandular cells should stain (HPA: High in breast glandular cells). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); on the breast slide, treat cells without specific staining as internal negatives only after confirming their background appearance with the no-primary control.

Positive control tissue: Breast (Glandular cells, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show HDAC6 in A-431, U-251MG, U2OS, HeLa, Rh30, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), Sperm, KOLF2.1J, with annotated localisation: Centrosome (supported), Basal body (supported), Cytosol (supported) (HPA subcellular).

Technical controls: Include no-primary (secondary-only) and concentration-matched rabbit isotype controls, plus HDAC6 knockout tissue or a peptide-block control if the immunizing peptide is available (PB9628 tissue-IHC caption: rabbit primary antibody; standard IHC controls). Block endogenous peroxidase and check background before interpreting HRP/DAB staining in breast sections (PB9628 tissue-IHC caption: HRP/DAB detection; standard IHC practice).

⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected PB9628 tissue-IHC caption does not state the fixative (PB9628 tissue-IHC caption: fixative not stated). Paraffin-section IHC is demonstrated with heat-mediated retrieval in EDTA, pH 8.0; retrieval dependence beyond that protocol is unreported (PB9628 tissue-IHC caption: paraffin section and EDTA retrieval). HPA shows ICC-IF images but provides no basis to say frozen sections or IF are easier, and no breast-specific artefact is reported in the supplied evidence (HPA: ICC-IF cell-line images; PB9628 tissue-IHC caption).

HPA tissue IHC evidence for HDAC6

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Breast	Glandular cells	High	Protein (IHC)	HPA →
Skin	Keratinocytes	High	Protein (IHC)	HPA →
Testis	Pachytene spermatocytes	High	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Medium	Protein (IHC)	HPA →
Appendix	Glandular cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Bronchus	Basal cells	Not detected	Protein (IHC)	HPA →
Hippocampus	Glial cells	Not detected	Protein (IHC)	HPA →
Skeletal muscle	Myocytes	Not detected	Protein (IHC)	HPA →
Smooth muscle	Smooth muscle cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced HDAC6 IHC Tips

Troubleshoot HDAC6 staining in paraffin sections by checking retrieval, compartment, tissue context, and controls before assigning a biological interpretation.

Which antigen retrieval should I try first for HDAC6 in paraffin sections?

Start with heat-mediated retrieval in EDTA, pH 8.0 (datasheet PB9628). The catalog antibody detected HDAC6 in a paraffin section of human breast cancer after this retrieval, with primary antibody at 2 μg/ml overnight at 4°C (PB9628 tissue-IHC caption). If staining is weak, check heating consistency, section adherence, and reagent performance before comparing a second retrieval condition on matched sections (standard IHC practice). The caption does not report the fixative, so its result does not establish how this antibody performs after any particular fixation method (PB9628 tissue-IHC caption).

Could fixation explain weak or uneven HDAC6 staining?

Target-specific sensitivity to fixation is unknown because the selected tissue-IHC caption calls the section paraffin embedded but does not state its fixative (PB9628 tissue-IHC caption). Record the specimen’s actual fixation and processing history, then compare affected sections with consistently processed controls using the same EDTA, pH 8.0 retrieval (standard IHC practice; datasheet PB9628). Check whether weak staining tracks with processing batches or section depth before changing antibody concentration (standard IHC practice). HDAC6 localization and modified residues do not establish a fixation effect, so avoid assigning a nuclear or cytoplasmic difference to fixation without a controlled comparison (UniProt Q9UBN7; standard IHC practice).

Is nuclear HDAC6 staining plausible when the expected pattern is cytoplasmic?

HDAC6 is mainly cytoplasmic and associated with microtubules, while nuclear localization is also reported under particular conditions (UniProt Q9UBN7). Cytosol, centrosome, and basal body are supported locations; nucleoplasm is an additional uncertain location (HPA subcellular). Score cytoplasmic and nuclear signal separately in intact cells, using a counterstain to define nuclei and matched negative controls to assess nonspecific chromogen (standard IHC practice). A reproducible nuclear pattern may merit biological follow-up, but a single nuclear-positive section cannot establish the relevant condition or HDAC6 activity (UniProt Q9UBN7; standard IHC practice).

How can I assess whether the antibody recognizes both HDAC6 isoforms?

UniProt lists 2 HDAC6 isoforms, but the supplied product caption does not identify the antibody’s epitope or demonstrate isoform-specific detection (UniProt Q9UBN7; PB9628 tissue-IHC caption). Obtain the mapped immunogen or epitope information and compare it with both isoform sequences before claiming shared recognition (standard antibody validation practice). HDAC6 has no annotated transmembrane segment and has reported modified residues, including threonines at positions 1016, 1021, and 1027; those facts alone do not identify this antibody’s binding site (UniProt Q9UBN7). If isoform attribution matters, corroborate the tissue pattern with an independently mapped reagent or an appropriate loss-of-target control (standard IHC practice).

How should I follow up an IHC HDAC6 pattern with multiplex IF?

Use IF as a separate validation experiment for a spatial pattern first observed by chromogenic IHC; the supplied PB9628 tissue caption documents paraffin-section IHC, not an IF protocol (PB9628 tissue-IHC caption). Pair HDAC6 with a validated marker for the cell population being scored, and include single-label controls to check channel overlap (standard IF practice). Select a fluorophore channel with low tissue autofluorescence, measuring an unstained section before setting exposure or thresholds (standard IF practice). Because HDAC6 has no transmembrane segment and is mainly cytoplasmic, test permeabilisation that gives access to the relevant intracellular epitope once that epitope is known (UniProt Q9UBN7; standard IF practice).

What should I check when DAB staining looks diffuse or widespread?

First compare a no-primary control and tissue morphology to distinguish antibody-dependent staining from endogenous peroxidase or deposited chromogen (standard IHC practice). The selected workflow used 10% goat serum blocking, a peroxidase-conjugated secondary for 30 minutes at 37°C, and DAB development (PB9628 tissue-IHC caption). Check that the peroxidase block, washes, and development time are consistent across sections; these are general chromogenic workflow controls, not HDAC6-specific validation (standard IHC practice). Broad cytoplasmic staining is biologically plausible because HPA reports cytoplasmic expression in most cell types, so judge excess background against controls and cell detail rather than breadth alone (HPA tissue IHC).

How should I score HDAC6 staining across heterogeneous tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and region of interest before scoring, then report the percentage of positive cells and an intensity-based H-score using identical thresholds across slides (standard IHC practice). Score cytoplasmic and nuclear signal separately because HDAC6 is mainly cytoplasmic but can enter the nucleus (UniProt Q9UBN7). Normalize positive counts to the number of evaluable cells in the same compartment, or report positive-cell density per mm² of viable tissue when cell counting is impractical (standard IHC practice). Keep retrieval, DAB development, imaging, and exclusion of damaged or necrotic areas consistent across groups (standard IHC practice).

How can I distinguish a true HDAC6-positive region from an artefact?

A credible result shows intracellular staining in intact cells with a pattern compatible with predominantly cytoplasmic HDAC6 and with the matched negative control remaining appropriately clear (UniProt Q9UBN7; standard IHC practice). HPA reports high staining in breast glandular cells, skin keratinocytes, and pachytene spermatocytes, but its tissue-IHC reliability note cites low consistency with RNA expression (HPA tissue IHC). Treat signal confined to section edges, necrotic areas, or morphologically implausible cells cautiously, and check for endogenous peroxidase contribution with a no-primary control (standard IHC practice). Reproducibility in matched sections supports an observation; localization alone does not establish HDAC6 enzymatic activity (standard IHC practice).

Boster reagents

Best HDAC6 / Protein deacetylase HDAC6 IHC Antibodies

PB9628 has a chromogenic IHC example in a paraffin-embedded human breast-cancer section (PB9628 image caption). Its listed reactivity covers human, mouse and rat (PB9628 catalog).

Real IHC data

Anti-HDAC6 Antibody ®

Cat # PB9628

View product →

PB9628 is the card SKU, with IHC shown in a paraffin-embedded human breast-cancer section (PB9628 image caption). Its applications include IHC, and its listed reactivity is human, mouse and rat; the pictured IHC result is human tissue (PB9628 catalog; PB9628 image caption).

Which to pick: Choose PB9628 for tissue IHC: its caption documents paraffin sections, EDTA retrieval at pH 8.0, and 2 μg/ml primary antibody; the fixative is unreported (PB9628 image caption). For human IF/ICC, M00595 is a rabbit monoclonal listed for both applications at 1:50, though no IF image is provided (M00595 catalog). For work across human, mouse and rat, PB9628 has the broader listed reactivity; its pictured IHC example supports human tissue only (PB9628 catalog; PB9628 image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q9UBN7 (HDAC6_HUMAN, Protein deacetylase HDAC6).
Human Protein Atlas. HDAC6 tissue IHC expression (reliability: Supported).
Human Protein Atlas. HDAC6 subcellular location (ICC-IF): Mainly localized to the cytosol, centrosome and basal body. In addition localized to the nucleoplasm..
Human Protein Atlas. HDAC6 antibody validation summary (3 antibodies).
Histone deacetylase 6 and programmed death ligand-1 expressions after neoadjuvant chemotherapy are upregulated in patients with ovarian high-grade serous carcinoma. Scientific reports 2025 — PMC12127455.
Immune Infiltration and Mitochondrial Function in Diabetic Kidney Disease: WGCNA and Machine Learning Identified Hub Genes with Clinical Validation. International journal of molecular sciences 2026 — PMC13256419.
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells. Cancers 2020 — PMC7762972.
Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients. Cancer management and research 2020 — PMC7751721.
PubMed PMID:10220385 — UniProt-cited evidence.
PubMed PMID:10048485 — UniProt-cited evidence.
PubMed PMID:15772651 — UniProt-cited evidence.